Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase


Study Number
1567721
Phase
N/A
Age Group
Adult
Purpose

This program provides access to asciminib for patients with CML in chronic phase, with or without documented T315I mutation, without comparable or satisfactory alternative therapy to treat the disease

Full Title

Managed Access Program (MAP)* to provide access to asciminib for patients with CML in chronic phase, with or without documented T315I mutation, without comparable or satisfactory alternative therapy to treat the disease

ClinicalTrials.Gov ID
NCT04360005

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.